This is the authors' abstract. We don't add key points for this paper.
Antivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirus-based replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equine encephalitis virus nonstructural and Sindbis virus structural components, induced efficient protective antibody responses, which were not adversely influenced after multiple immunizations with the same vector expressing various antigens.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Uematsu et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: